Avalo CMO exercises options, sells 679 shares
Avalo Therapeutics, Inc. (AVTX) reported that Chief Medical Officer Mittie Doyle exercised stock options for 679 shares of common stock at an exercise price of $8.04 per share and on the same day sold 679 shares of common stock at $20.00 per share.
Rhea-AI Filing Summary
Avalo Therapeutics, Inc. (AVTX) reported that Chief Medical Officer Mittie Doyle exercised stock options for 679 shares of common stock at an exercise price of $8.04 per share and on the same day sold 679 shares of common stock at $20.00 per share. After the option exercise, Doyle held 113,734 stock options directly. All transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025, and the underlying option grant vests 25% on January 28, 2026, with the remainder vesting in equal monthly installments over the following three years.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 679 shares ($8K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Doyle Mittie
Role
Chief Medical Officer
Sold
679 shs ($14K)
Approx. gross sale proceeds
$14K
Approx. exercise cost
$5K
Approx. pre-tax spread
$8K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F2 | 679 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 679 | $8.04 | $5K |
| Sale | Common Stock F1 | 679 | $20.00 | $14K |
Holdings After Transaction:
Stock Option (Right to Buy) — 113,734 contracts (Direct);
Common Stock — 51,776 shares (Direct)
Footnotes (2)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Options exercised: 679 shares
Option exercise price: $8.04 per share
Shares sold: 679 shares
+4 more
7 metrics
Options exercised
679 shares
Stock Option (Right to Buy) exercised on August 28, 2026
Option exercise price
$8.04 per share
Exercise or conversion of derivative security into common stock
Shares sold
679 shares
Sale of common stock on August 28, 2026
Sale price
$20.00 per share
Sale of 679 shares of common stock
Stock options outstanding after transaction
113,734 options
Total stock options following the reported derivative transaction
Option expiration date
January 28, 2035
Expiration of the stock option relating to the exercised shares
Initial vesting portion
25%
Vests on January 28, 2026, with remaining vesting monthly over three years
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), Exercise or conversion of derivative security, vesting, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
vesting financial
"The stock option vests twenty-five percent (25%) on January 28, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2035-01-28""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What insider transactions did AVTX Chief Medical Officer Mittie Doyle report?
Mittie Doyle reported exercising stock options for 679 shares of Avalo Therapeutics common stock at $8.04 per share and selling 679 shares of common stock at $20.00 per share on August 28, 2026, in transactions reported on Form 4.
Was the AVTX insider trading activity under a Rule 10b5-1 plan?
Yes. The Form 4 states that all reported transactions were effected under a Rule 10b5-1 trading plan adopted by Mittie Doyle on November 13, 2025, indicating the trades were made pursuant to a pre-arranged plan.
What stock option terms apply to Mittie Doyle’s AVTX grant?
The stock option referenced vests 25% on January 28, 2026, with the remaining portion vesting in equal monthly installments over three years, subject to Doyle’s continued service on each vesting date. The option has an exercise price of $8.04 per share and expires on January 28, 2035.
How many AVTX stock options does Mittie Doyle hold after these transactions?
Following the reported option exercise, Mittie Doyle directly held 113,734 stock options of Avalo Therapeutics, according to the Form 4 derivative holdings field tied to the exercised option.
What prices were involved in the AVTX insider’s exercise and sale?
The Form 4 shows an option exercise price of $8.04 per share for 679 shares of common stock and a sale price of $20.00 per share for 679 shares of common stock, both dated August 28, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
